Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CBM-588 by Miyarisan Pharmaceutical for Metastatic Renal Cell Carcinoma: Likelihood of Approval
CBM-588 is under clinical development by Miyarisan Pharmaceutical and currently in Phase I for Metastatic Renal Cell Carcinoma. According to...